Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDIFZ5CYGW)
  Drug Name Aldesleukin Drug Info Diltiazem Drug Info
  Drug Type Interferons Small molecule
  Therapeutic Class Antineoplastics Antihypertensive Agents

 Mechanism of Aldesleukin-Diltiazem Interaction (Severity Level: Moderate)
     Additive hypotensive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Aldesleukin Diltiazem
      Mechanism 1 Antihypertensive agent Antihypertensive agent
Voltage-gated calcium channel  Blocker
      Key Mechanism Factor 1
Factor Name Voltage-dependent L-type calcium channel Structure Sequence
Protein Family Calcium channel beta subunit family
Protein Function
Regulatory subunit of L-type calcium channels (PubMed:1309651, PubMed:8107964, PubMed:15615847). Regulates the activity of L-type calcium channels that contain CACNA1A as pore-forming subunit (By similarity). Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming subunit and increases the presence of the channel complex at the cell membrane (PubMed:15615847). Required for functional expression L-type calcium channels that contain CACNA1D as pore-forming subunit (PubMed:1309651). Regulates the activity of L-type calcium channels that contain CACNA1B as pore-forming subunit (PubMed:8107964).
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Aldesleukin and Diltiazem 
      Mechanism 2 Hypotensive effects Antihypertensive agent
Voltage-gated calcium channel  Blocker
      Key Mechanism Factor 2
Factor Name Voltage-dependent L-type calcium channel Structure Sequence
Protein Family Calcium channel beta subunit family
Protein Function
Regulatory subunit of L-type calcium channels (PubMed:1309651, PubMed:8107964, PubMed:15615847). Regulates the activity of L-type calcium channels that contain CACNA1A as pore-forming subunit (By similarity). Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming subunit and increases the presence of the channel complex at the cell membrane (PubMed:15615847). Required for functional expression L-type calcium channels that contain CACNA1D as pore-forming subunit (PubMed:1309651). Regulates the activity of L-type calcium channels that contain CACNA1B as pore-forming subunit (PubMed:8107964).
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Aldesleukin and Diltiazem 

Recommended Action
      Management Blood pressure should be monitored during concomitant administration. Aldesleukin doses should be held if systolic blood pressure falls to less than 90 mmHg.

References
1 Product Information. Proleukin (aldesleukin). Chiron Therapeutics, Emeryville, CA.